U.S. FDA Lifts Clinical Hold On Viking Therapeutics' Initial-Stage Genetic Disorder Study
Viking Therapeutics (NASDAQ: VKTX) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).
